Axial Spondyloarthritis (axSpA) Market Expansion Continues, with Forecast Valuation of $9.05 Billion by 2029

"Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Axial Spondyloarthritis (axSpA) Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for axial spondyloarthritis (axspa) has seen robust growth in the past few years. It is projected to expand from $6.08 billion in 2024 to $6.58 billion in 2025, growing at a compound annual growth rate (CAGR) of 8.3%. The growth during the historic period is credited to the enhancement in diagnostic criteria, advancements in biological treatments, an increase in disease awareness, progress in genetic research, and advancements in clinical trials.

Axial Spondyloarthritis (axSpA) Market Size Forecast: What's the Projected Valuation by 2029?
Anticipated robust expansion is in the offing for the axial spondyloarthritis (axspa) market in the coming years, as it is predicted to reach $9.05 billion by 2029, with a compound annual growth rate (CAGR) of 8.3%. Growth within the projection period can be credited to advancements such as biomarker identification, personalized therapies, incorporation of digital health, extended treatment alternatives, and backing from healthcare policies. Through the forecast period, major trends encompass early intervention approaches, focus on patient-centric care, the use of telemedicine and remote consultations, research on disease functionality, and collective decision-making.

View the full report here:
https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report

What Are the Drivers Transforming the Axial Spondyloarthritis (axSpA) Market?
The axial spondyloarthritis (axSpa) market's growth is predicted to be propelled by the escalating incidence of spondyloarthritis. This chronic disease predominantly impacts the axial skeleton, especially the spine and sacroiliac joints. The rising instances of axSpA are linked to the increasing aging population and spine injuries from minor falls or any other accidents. Various treatments are provided to manage pain, control inflammation, and improve the life quality of axSpA patients. For instance, the Musculoskeletal Health Report 2023 by Versus Arthritis-a UK-based charity dedicated to assisting those with arthritis-reported that in 2022, approximately 60,000 people suffered from axial spondyloarthritis, and each year around 2,200 adults are newly diagnosed with this condition. Hence, the rising incidence of axSpa is bolstering the growth of the axSpa market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12590&type=smp

What Long-Term Trends Will Define the Future of the Axial Spondyloarthritis (axSpA) Market?
The primary trend that is gaining traction in the axial spondyloarthritis (axSpA) market is product innovation. Major firms participating in the axial spondyloarthritis (axSpA) market are creating new medicines to maintain their market presence. An example of this occurred in June 2023 when UCB SA, a pharmaceutical company based in Belgium, got a green light from the New European Commission to market BIMZELX (bimekizumab). This drug is prescribed to adults suffering from active axial spondyloarthritis (axSpA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS), who show visible signs of inflammation as evidenced by increased C-reactive protein levels. The European Union (EU) granted these authorizations, marking the drug's maiden global marketing licenses for axial spondyloarthritis.

Which Segments in the Axial Spondyloarthritis (axSpA) Market Offer the Most Profit Potential?
The axial spondyloarthritis (axSpA) market covered in this report is segmented -

1) By Types: Ankylosing Spondylitis (AS), Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
2) By Commercialized Therapies: Anti-Tumor Necrosis Factor Therapy (TNF), Anti-Interleukin Therapy (IL), Anti-Janus Kinase Therapy (JAK)
3) By Dosage Form: Tablets, Injections
4) By Treatment: Tumor Necrosis Factor (TNF) Alpha Inhibitors, Non-Steroidal Anti-Inflammatory Drugs (NSAID), Conventional Disease Modifying Anti-Rheumatic Drugs, Glucocorticoids, Interleukin Blockers
5) By End-Use: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacy Stores

Subsegments:
1) By Ankylosing Spondylitis (AS): Early-stage AS, Advanced-stage AS
2) By Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Symptomatic nr-axSpA, Asymptomatic nr-axSpA

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12590&type=smp

Which Firms Dominate the Axial Spondyloarthritis (axSpA) Market by Market Share and Revenue in 2025?
Major companies operating in the axial spondyloarthritis (axSpA) market include Johnson and Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, Merck and Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca plc., Abbott Laboratories, GSK plc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, UCB S.A., Boehringer Ingelheim International GmbH., Horizon Therapeutics Public Ltd Co, Mitsubishi Tanabe Pharma Corporation, Ipsen Technologies Pvt Ltd., Kyowa Kirin Co. Ltd., Sun Pharmaceutical Industries Ltd., Acelyrin Inc., Nordic Bioscience A/S, Iroko Pharmaceuticals LLC

Which Regions Offer the Highest Growth Potential in the Axial Spondyloarthritis (axSpA) Market?
North America was the largest region in the axial spondyloarthritis(axSpA) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the axial spondyloarthritis (axSpA) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12590

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Contact Us:
The Business Research Company
Europe - +44 7882 955267
Asia: +91 88972 63534
Americas - +1 310-496-7795
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.

Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.

This release was published on openPR.